Loading
A phase 3 trial testing RC148 in non-small-cell lung cancer, now recruiting.
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) is a phase 3 interventional study registered as NCT07416474, led by RemeGen, and recruiting on the registry. Official title: Randomised, Double-Blind, Multicenter Phase III Study of RC148 in Combination With Platinum-Based Chemotherapy Versus Tislelizumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer. Planned enrolment is 574 participants (estimated). The study started in 2026-04-03 and primary completion is expected in 2027-12-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RemeGen, Non-small-cell lung cancer.
Shares Squamous cell carcinoma of the lung, Non-small-cell lung cancer.
Shares RemeGen, Non-small-cell lung cancer.
Shares Squamous cell carcinoma of the lung, Non-small-cell lung cancer.
Shares Squamous cell carcinoma of the lung, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/